Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment
- Conditions
- Acquired Pure Red Cell Aplasia
- Interventions
- Drug: bortezomib/dexamethasone
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-11-18
- Target Recruit Count
- 18
- Registration Number
- NCT04423367
- Locations
- 🇨🇳
The Second Affilated Hospital of Shandong First Medical University, Tai'an, Shandong, China
🇨🇳Regenerative Medicine Center, Tianjin, China
🇨🇳Zhoukou Central Hospital, Zhoukou, Henan, China
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
- Conditions
- Refractory/Relapsed Autoimmune Hemolytic Anemia
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-02-12
- Target Recruit Count
- 18
- Registration Number
- NCT04398459
- Locations
- 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳The Second Affilated Hospital of Shandong First Medical University, Tai'an, Shandong, China
🇨🇳Regenerative Medicine Center, Tianjin, Tianjin, China
Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia
- Conditions
- Transfusion Dependent Beta-Thalassaemia
- Interventions
- Biological: ET-01
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2023-11-27
- Target Recruit Count
- 3
- Registration Number
- NCT04390971
- Locations
- 🇨🇳
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
🇨🇳Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2020-03-26
- Target Recruit Count
- 10
- Registration Number
- NCT04322292
- Locations
- 🇨🇳
InstituteHBDH, TianJin, China
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-07-19
- Target Recruit Count
- 7
- Registration Number
- NCT04316624
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
- Conditions
- Essential Thrombocytopenia
- Interventions
- Drug: Recombinant Interferon AlphaDrug: Pegylated interferon alfa-2b
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 40
- Registration Number
- NCT04226950
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Gene Therapy for Chinese Hemophilia B
- Conditions
- Hemophilia B
- Interventions
- Genetic: Single dose intravenous injection of BBM-H901
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 10
- Registration Number
- NCT04135300
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
- Conditions
- Transformed LymphomaPrimary Mediastinal Large B Cell LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma
- Interventions
- Biological: BZ019
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2020-03-17
- Target Recruit Count
- 12
- Registration Number
- NCT04067414
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: CD19-CD22 CAR-T cells
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2022-08-03
- Target Recruit Count
- 2
- Registration Number
- NCT04034446
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Non-Hodgkin's LymphomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaPeripheral T Cell LymphomaChronic Lymphoblastic Leukemia
- Interventions
- Biological: Autologous γδT cells
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2019-09-26
- Target Recruit Count
- 6
- Registration Number
- NCT04028440
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China